CoChat

FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM)

Maiello, E., Giuliani, F., Gebbia, V., Di Renzo, N., Pezzella, G., Romito, S., Mallamaci, R., Lopez, M., Colucci, G. · 2006 · Annals of Oncology
Cited by 25

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdl952

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 18

  1. Douillard, 2000, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial, Lancet, 355, 1041, 10.1016/S0140-6736(00)02034-1 · DOI · Paper page
  2. De Gramont, 2000, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol, 18, 2938, 10.1200/JCO.2000.18.16.2938 · DOI · Paper page
  3. Colucci, 2005, Phase III randomized trial of FOLFIRI vs FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico dell’Italia Meridionale (GOIM), J Clin Oncol, 23, 4866, 10.1200/JCO.2005.07.113 · DOI · Paper page
  4. Dannenberg, 2001, Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer, Lancet Oncol, 2, 544, 10.1016/S1470-2045(01)00488-0 · DOI · Paper page
  5. Yamauchi, 2002, Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer, Dis Colon Rectum, 45, 98, 10.1007/s10350-004-6120-5 · DOI
  6. Gupta, 2001, Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2, Nat Rew Cancer, 1, 11, 10.1038/35094017 · DOI · Paper page
  7. Arber, 1999, Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer, Curr Gastroenteral Rep, 1, 441, 10.1007/s11894-999-0027-1 · DOI
  8. Church, 2003, Cyclo-oxygenase 2 inhibition in colorectal cancer therapy, Br J Surg, 90, 1055, 10.1002/bjs.4297 · DOI
  9. Thun, 2002, Non-steroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues, J Natl Cancer Inst, 94, 252, 10.1093/jnci/94.4.252 · DOI · Paper page
  10. Therrasse, 2000, New guidelines toevaluate the response to treatment in solid tumors, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 · DOI · Paper page
  11. Blanke, 2002, A phase II trial of celecoxib, irinotecan, 5-fluorourail, and leucovorin in patients with unresectable or metastatic colorectal cancer: Proc, Am Soc Clin Oncol, 505, 21
  12. Saltz, 2000, Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group, N Engl J Med, 343, 905, 10.1056/NEJM200009283431302 · DOI · Paper page
  13. Pan, 2003, A phase II trial of irinotecan, 5-fluorouracil, leucovorin (IFL), celecoxib and glutamine as first line therapy for advanced colorectal cancer: A Hoosier Oncology Group study, Proc Am Soc Clin Oncol, 1347, 22
  14. Lin, 2002, Ayers GD. effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity, Oncology, 16, 31
  15. Becerra, 2003, Increased toxicity and lack of efficacy of rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer. A phase II study, Int J Cancer, 105, 868, 10.1002/ijc.11164 · DOI
  16. Gasparini, 2005, Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer, The Oncologist, 10, 710, 10.1634/theoncologist.10-9-710 · DOI
  17. Maiello, 2000, 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: A multicenter randomized phase II study of the Southern Italy Oncology group, Ann Oncol, 11, 1045, 10.1023/A:1008342928408 · DOI
  18. Solomon, 2005, Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention, N Engl Med J, 353, 1071, 10.1056/NEJMoa050405 · DOI · Paper page

Cited by

See all 25

Metadata

Authors
Maiello, E., Giuliani, F., Gebbia, V., Di Renzo, N., Pezzella, G., Romito, S., Mallamaci, R., Lopez, M., & Colucci, G.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2006-06
Volume
17
Pages
vii55-vii59
ISSN
0923-7534
Cited by
25
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.